OXERVATE® Indication and Important Safety Information скачать в хорошем качестве

OXERVATE® Indication and Important Safety Information

Visit https://www.oxervate.com/prescribing-... to see Full Prescribing Information. Watch to view Oxervate Indication and Important Safety Information. Important Safety Information WARNINGS AND PRECAUTIONS Use with Contact Lens Contact lenses should be removed before applying OXERVATE because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin-bkbj onto the area of the corneal lesion. Lenses may be reinserted 15 minutes after administration. Eye Discomfort OXERVATE may cause mild to moderate eye discomfort such as eye pain during treatment. The patient should be advised to contact their doctor if a more serious eye reaction occurs. ADVERSE REACTIONS In clinical trials, the most common adverse reaction was eye pain following instillation which was reported in approximately 16% of patients. Eye pain may arise as corneal healing occurs. Other adverse reactions occurring in 1% to 10% of OXERVATE patients included corneal deposits, foreign body sensation, ocular hyperemia, ocular inflammation, photophobia, tearing, and headache. USE IN SPECIFIC POPULATIONS Pregnancy There are no data from the use of OXERVATE in pregnant women to inform any drug associated risks. Lactation The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for OXERVATE, and any potential adverse effects on the breastfed infant from OXERVATE. Pediatric Use The safety and effectiveness of OXERVATE have been established in the pediatric population. Use of OXERVATE in pediatric patients 2 years of age and older is supported by evidence from adequate and well-controlled trials of OXERVATE in adults with additional safety data in children. INDICATION OXERVATE® (cenegermin-bkbj) ophthalmic solution 0.002% (20 mcg/mL) is indicated for the treatment of neurotrophic keratitis. DOSAGE AND ADMINISTRATION Instill one drop of OXERVATE in the affected eye(s), 6 times a day at 2-hour intervals for eight weeks. To report ADVERSE REACTIONS, contact Dompé U.S. Inc. at 1-833-366-7387 or FDA at 1-800-FDA-1088 or https://www.fda.gov/medwatch. Please see full Prescribing Information for OXERVATE, available at https://www.oxervate.com/prescribing-...